We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

227 hedge funds and large institutions have $1.56B invested in Syndax Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 72 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $25M | Put options by funds: $12.5M

63% more capital invested

Capital invested by funds: $953M → $1.56B (+$603M)

46% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 28

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

13% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 72

5% more funds holding

Funds holding: 216 → 227 (+11)

0.85% less ownership

Funds ownership: 118.22% → 117.38% (-0.85%)

Holders
227
Holders Change
+11
Holders Change %
+5.09%
% of All Funds
2.98%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.13%
New
41
Increased
81
Reduced
72
Closed
28
Calls
$25M
Puts
$12.5M
Net Calls
+$12.5M
Net Calls Change
+$10.7M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$27.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$24.6M
3
MB
MPM BioImpact
Massachusetts
+$18M
4
N
Nuveen
North Carolina
+$15.8M
5
SCM
Soleus Capital Management
Connecticut
+$12M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$24M
2
SFM
Sphera Funds Management
Israel
-$15.5M
3
SI
Sofinnova Investments
California
-$14.3M
4
SC
Stempoint Capital
New York
-$13.2M
5
EP
Eversept Partners
New York
-$7.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$16.2M +$10.7M +815,234 +344%
Millennium Management
27
Millennium Management
New York
$16.1M -$7.23M -552,157 -35%
PM
28
Prosight Management
Texas
$15.4M -$998K -76,273 -7%
EAM
29
Eventide Asset Management
Massachusetts
$15.2M -$5.57M -425,595 -30%
AG
30
Algert Global
California
$14.3M -$1.18M -90,514 -9%
CS
31
Candriam SCA
Luxembourg
$14.2M +$3.28M +250,247 +37%
Renaissance Technologies
32
Renaissance Technologies
New York
$13.2M +$298K +22,800 +3%
PHP
33
Parkman Healthcare Partners
Connecticut
$13M -$274K -20,914 -2%
Ensign Peak Advisors
34
Ensign Peak Advisors
Utah
$12.4M +$1.57M +120,000 +17%
Northern Trust
35
Northern Trust
Illinois
$11.9M +$81.6K +6,235 +0.8%
Jane Street
36
Jane Street
New York
$11.4M +$7.47M +570,773 +341%
Charles Schwab
37
Charles Schwab
California
$11.1M +$88K +6,724 +0.9%
Two Sigma Investments
38
Two Sigma Investments
New York
$11M +$2.04M +155,688 +28%
PAI
39
Palo Alto Investors
California
$10.1M +$2.76M +210,563 +47%
ACA
40
Apis Capital Advisors
New York
$9.82M +$8.35M +638,000 New
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$9.23M +$1.31M +99,968 +20%
RPAM
42
Rhenman & Partners Asset Management
Sweden
$8.83M – – –
AQR Capital Management
43
AQR Capital Management
Connecticut
$8.59M +$4.29M +327,499 +142%
Citadel Advisors
44
Citadel Advisors
Florida
$8.4M -$1.23M -93,732 -15%
DCM
45
DAFNA Capital Management
California
$7.7M -$562K -42,900 -8%
SCM
46
Silverarc Capital Management
Massachusetts
$7.13M +$795K +60,744 +15%
DMKJ
47
David M. Knott Jr
$6.58M +$985K +75,222 +21%
GIM
48
Granahan Investment Management
Massachusetts
$6.1M -$7.79M -595,052 -60%
SFM
49
Sphera Funds Management
Israel
$5.97M -$15.5M -1,183,848 -75%
ZP
50
Zimmer Partners
New York
$5.89M -$2.91M -222,700 -37%
1
2
3 4 5

SNDX Hedge Fund Activity: Q3 2025 in Review

227 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2025, worth a combined $1.56B — up 63% from $953M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new SNDX positions and 28 closed out — a net gain of 13 holders — while 81 added to existing stakes and 72 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $27.8M. The largest seller was BlackRock, cutting an estimated $24M.

  • 227 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2025, up from 216 in Q2 2025.
  • Funds reported $1.56B of Syndax Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
  • 41 funds opened new Syndax Pharmaceuticals positions in Q3 2025 and 28 closed out, a net change of +13 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2025 was Point72 Asset Management, an estimated $27.8M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2025 was BlackRock, an estimated $24M sold.

Based on aggregated 13F filings for Q3 2025.